[Question] Denmark — has anyone got a straight answer on 503B
Genuine question, and the title is the question: Denmark — has anyone got a straight answer on 503B.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number
Agreed — and the follow-up question is what the beyond-use date is based on.
the label on a compounded vial is a legal document, read it
a 503B has to register and report, so there is a paper trail to ask for
a 503B has to register and report, so there is a paper trail to ask for
Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.
a telehealth intake that asks nothing has told you what it is
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
ask which facility, then ask for their testing
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
shortage status changes and the whole arrangement changes with it
potency testing on the finished preparation is the thing to ask for
the price difference is mostly the intake, not the vial
- 1Salt form matters for mass: a preparation specified as one salt and dosed as…10 comments in this branch · started by u/mikkel_correia
- 2Potency and sterility testing on the finished preparation are separate from…10 comments in this branch · started by u/solene_eriksen